Navigation Links
Wake Forest scientists find new combination vaccine effective against plague

Plague, a bacterium that ravaged Europe in the Middle Ages and is today one of the most feared potential agents of bio-terrorism, may have met its match, according to Wake Forest University School of Medicine scientists.

Steven B. Mizel, Ph.D., principal investigator, told the American Gastroenterological Association meeting in Chicago that when mice immunized with a new combination vaccine were challenged with a lethal dose of Yersinia pestis, the bacterium that causes plague, "the immune mice survived but the control mice succumbed in three days."

Mizel and his graduate student, Anna Honko, found that injecting a protein taken from plague bacteria into a mouse ?one method of vaccination ?produces little if any response in the mouse immune system. But if a protein termed flagellin is added to the vaccine, antibody levels against the plague bacteria are 500,000 times higher.

"Flagellin can function as an effective adjuvant, making a vaccine that protects against the most dangerous form of the plague ?pneumonic plague," reported Mizel, professor and chairman of the Department of Microbiology and Immunology at the School of Medicine, part of Wake Forest University Baptist Medical Center in Winston-Salem.

Pneumonic plague occurs when an individual breathes in plague bacteria. Untreated, the victim dies within three to four days. "We have also established that flagellin is an effective adjuvant in monkeys immunized with flagellin and a Yersina pestis antigen," he said. "The immunized monkeys showed no undesired effects from the vaccine. There was no fever or other signs of problems.

"These results clearly establish a strong foundation for the future use of flagellin as an adjuvant in humans," Mizel said.

He said the research shows that the mice were protected for at least three months after immunization.

The work is part of a $9.125 million, five-year research program funded by the National Institutes of Health unde r a federal bioterrorism initiative. "The development of a vaccine against the pneumonic or respiratory form of plague is a major goal of the bio-defense initiative," he said.

The research program involves six other medical school scientists and a secure biosafety laboratory at Virginia Tech that is certified by the Centers for Disease Control and Prevention and the FBI to work with dangerous pathogens. Mizel said the actual challenges of vaccines against plague are occurring in that safe laboratory in Blacksburg, Va., and not in Winston-Salem.

Flagellin is taken from bacterial flagella, whiplike appendages that are used by bacteria to move around their environment. Thus it is possible for animals that have been exposed to a different bacterial infection to have antibodies against flagellin. But Mizel and his colleagues found that flagellin is equally effective in animals with such antibodies as it is in mice that had never encountered flagellin before.

"Prior immunity to flagellin does not impair its ability to function as an adjuvant," Mizel said. "This means that flagellin can be used multiple times with different types of vaccines. The new plague vaccine also has the advantage of not requiring a needle since only a few drops in the nose provide protection."

In view of the exciting results with the plague vaccine, Mizel plans to determine if immunized monkeys are protected against the plague. If they are then efforts will be initiated to begin studies in humans.


'"/>

Source:Wake Forest University Baptist Medical Center


Related biology news :

1. Revueltosaurus skeleton unearthed at Petrified Forest upsets dinosaur tale
2. Wisconsin scientists grow critical nerve cells
3. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
4. UAB scientists discover the origin of a mysterious physical force
5. Fox Chase Cancer Center scientists identify immune-system mutation
6. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
7. U-M scientists find genes that control growth of common skin cancer
8. UCLA scientists transform HIV into cancer-seeking missile
9. RNA project to create language for scientists worldwide
10. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
11. To control germs, scientists deploy tiny agents provocateurs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology: